ENGINEERING
- Display of Biologics
- Engineering Antibodies
- Machine Learning Part 2

TARGETS
- Antibody-Based Therapies
- Autoimmune Diseases NEW
- Challenging Targets

BISPECIFICS
- Safety & Efficacy
- Advancing Multispecifics
- Engineering Bispecifics

IMMUNOTHERAPY
- T Cell Engagers NEW
- Immunoengineering
- Next-Gen Immunotherapies

ANALYTICAL
- Optimisation & Developability
- Analytical Characterisation
- Protein Stability & Formulation

EXPRESSION
- Leveraging Data Science
- Omtimising Expression
- Developing Workflows

MACHINE LEARNING
- AI Driven Design
- Machine Learning Part 1
- Machine Learning Part 2

THERAPEUTICS
- Antibody-Based Therapies
- Engineering Conjugates
- Peptide Drug Discovery NEW

PREMIER SPONSORS

BIOINTRON danaher GenScript integral molecular

PEGSummitEurope.com

18th Annual

PEGS EUROPE

Protein & Antibody Engineering Summit

16-19 NOVEMBER 2026

Lisbon Congress Center | Lisbon, Portugal

"The Best Biologics Technology Meeting in Europe"

SAVE €600!

Register by 22 May

2026 PLENARY KEYNOTE SESSION

Emerging Modalities and the Future of Antibody Engineering

MODERATOR

Jennifer Cochran, PhD
Stanford University

The Making of Multispecific Antibodies —A Clinical Perspective
Roland Kontermann, PhD
University of Stuttgart

The Future of T Cell Engagers
Patrick Baeuerle, PhD
Cullinan Therapeutics, Inc.

ENGINEERING

17 NOVEMBER

Display of Biologics

COMBINATORIAL METHODS TO IMPROVE BIOLOGIC DISCOVERY: COMBINING DEEP SEQUENCING AND COMPUTATIONAL METHODS

Quantitative Screening and Characterisation of Macrocyclic Peptide Ligands Using Yeast Surface Display
Alessandro Angelini, PhD, Professor, Department of Molecular Sciences and Nanosystems, European Center for Living, Technology Ca' Foscari University of Venice

PANCS-Binders: A Rapid Binder Discovery Platform
Bryan Dickinson, PhD, Assistant Professor, Department of Chemistry, University of Chicago

Discovering Antibodies against Tumour Glyco-Epitopes: Structure-Guided Phage Display Targeting Tn/STn in Protein Context
Ola Blixt, PhD, CEO, Combotrope Therapeutics

HYBRID WORKFLOWS: AUGMENTING BIOLOGICS DISCOVERY WITH AI/ML

Augmenting Biologics Drug Discovery with Deep Screening and Machine Learning
Mark J. Austin, PhD, Team Leader, Display Technology, CRUK AstraZeneca Antibody Alliance Laboratory (AAL)

Integrating AI/ML and Next-Generation Sequencing for Accelerated Discovery of Single Domain Antibodies
Andreas Evers, PhD, Associate Scientific Director, Antibody Discovery & Protein Engineering, Global Research & Development Discovery Technology, Merck Healthcare KGaA

The Development of iSeRa-AI, a Tool for Automatic Selection of mAbs from Antibody Display Coupled to Deep Sequencing
André F. Faustino, PhD, Senior Scientist, iBET, Instituto de Biologia Experimental e Tecnológica

PANEL DISCUSSION:

Best Practices for *in silico* Design of Antibodies—What We Know Now
PANEL MODERATOR:
Rebecca Croasdale-Wood, PhD, Senior Director, Augmented Biologics Discovery & Design, Biologics Engineering, Oncology, AstraZeneca
PANELISTS:
Andrew R.M. Bradbury, MD, PhD, CSO, Specifica, an IQVIA business
Andreas Evers, PhD, Associate Scientific Director, Antibody Discovery & Protein Engineering, Global Research & Development Discovery Technology, Merck Healthcare KGaA

18 NOVEMBER

Engineering Antibodies & Beyond

PLENARY KEYNOTE SESSION

KEYNOTE PRESENTATION: **The Making of Multispecific Antibodies—A Clinical Perspective**
Roland Kontermann, PhD, Professor & Deputy Head, Biomedical Engineering, University of Stuttgart

KEYNOTE PRESENTATION: **The Future of T Cell Engagers**
Patrick Baeuerle, PhD, Chief Scientific Advisor, Cullinan Therapeutics, Inc.

FIRESIDE CHAT: **Emerging Modalities and the Future of Antibody Engineering**
PANEL MODERATOR:
Jennifer R. Cochran, PhD, Senior Associate Vice Provost for Research and Macovski Professor of Bioengineering, Stanford University
PANELISTS:
Patrick Baeuerle, PhD, Chief Scientific Advisor, Cullinan Therapeutics, Inc.
Roland Kontermann, PhD, Professor & Deputy Head, Biomedical Engineering, University of Stuttgart
Ulrike Philippar, PhD, Vice President Oncology, Global Head of Discovery, Johnson & Johnson Innovative Medicine

ENGINEERING SMARTER ANTIBODIES

KEYNOTE PRESENTATION: **Empowering Next-Generation Antibodies: Synergy of Conditional Activation and Fc Engineering**
Hitoshi Katada, PhD, Head of Biologics Engineering, Chugai Pharmaceutical Co. Ltd.

Next-Generation Conditionally Active Biologics: Field Landscape and *de novo*–Designed Masks
Benjami Oller-Salvia, PhD, Assistant Professor, "La Caixa" Junior Leader Fellow, Bioengineering, Protein and Peptide Targeted Nanotherapeutics Program, Ramon Llull University

Antibody Properties That Control Immune Receptor Signalling: Lessons from Affinity, Rigidity and Geometry
Mark S. Cragg, PhD, Professor, Experimental Cancer Biology, Antibody and Vaccine Group, School of Cancer Sciences, University of Southampton

ENGINEERING BISPECIFICS FOR SOLID TUMOURS

Breaking through the Solid Tumour Barrier
Mark L. Chiu, PhD, President, Qilin Glen LLC

TCAB: Tackling the Challenges of Solid Tumour-Targeting T Cell Bispecifics
Mireille Vankemmelbeke, PhD, Principal Scientist, Scancell, Ltd.

Advancing CD3 Bispecifics for Solid Tumour Indications
Alison Crawford, PhD, Director, Immuno-Oncology, Regeneron Pharmaceuticals

INTRACELLULAR TARGETING AND SYNTHETIC EFFECTORS

Engineering Cytosol-Penetrating Antibodies for Intracellular Delivery of Bio-Payloads and Solid Tumour Therapy
Yong-Sung Kim, PhD, Professor, Molecular Science & Technology, Ajou University, Korea

Targeting Intracellular Protein Interactions Using Antibody Fragment mRNA Expression Cargoes within Nanoparticle Delivery Vehicles
Terence Rabbitts, FRS, FMedSci, Professor, Molecular Immunology, Center for Cancer Drug Discovery, Institute of Cancer Research

Hijacking Ras Signaling: Synthetic Effectors for Selective Targeting of Pancreatic Cancer
Julia M. Shifman, PhD, Professor, Biological Chemistry, The Alexander Siblerman Institute for Life Sciences, The Hebrew University Jerusalem

19 NOVEMBER

Machine Learning for Protein Engineering Part 2

PANEL DISCUSSION: Generation of AI-Based Therapeutics
PANEL MODERATOR:
Andrew Buchanan, PhD, FRSC, Head of Discovery, Stealth Mode Biotech

PANELISTS:
Simon Kohl, PhD, Founder and CEO, Latent Labs
Jinwoo Leem, DPhil, Senior Machine Learning Research Scientist, Isomorphic Labs
Talip Uçar, Founding Member, Boltz

DE NOVO DESIGN OF PROTEIN THERAPEUTICS: TECHNOLOGY ADVANCES MEET REAL-WORLD APPLICATIONS

AI for Biologics: Transition from Discovery to Design
Yu Qiu, PhD, Executive Director, Biologics Design and Technology, AstraZeneca

***De novo* VHH Design in Practice: Bridging AI Innovation with Real-World Biologics Design**
Norbert Furtmann, PhD, Head, Biologics AI & Design, Large Molecules Research, Sanofi

FROM STRUCTURE PREDICTION TO *DE NOVO* VACCINE DESIGN

Structural Plausibility without Binding Specificity: Limits of AI-Based Antibody-Antigen Structure Prediction Confidence Scores
Eva Smorodina, PhD, Computational Structural Biologist, University of Oslo

Directed Evolution Informs Divergent Pathways of Antibody Affinity Maturation
Daniel Bader, Graduate Student, Scripps Research Institute

AGENTIC AI AND SELF-DRIVING LABS FOR BIOLOGICS DISCOVERY

An AI-Powered Biofoundry for Protein Discovery and Engineering
Huimin Zhao, PhD, Steven L. Miller Chair Professor, University of Illinois Urbana Champaign

Automating Biological Science
Ross D. King, PhD, Professor, Chemical Engineering & Biotechnology, University of Cambridge

Integrating Physics & Deep Learning for Antibody Design
Joost Schymkowitz, PhD, Professor & Group Leader, Switch Lab, VIB-KU Leuven

17 NOVEMBER
Antibody-Based Therapies

ANTIBODIES TO WATCH

Antibodies to Watch in 2027
Silvia Crescioli, PhD, Independent Consultant

NEXT-GENERATION ANTIBODY MODALITIES FOR IMMUNOMODULATION

KEYNOTE PRESENTATION: **Unlocking New Horizons: Anti-CD89 Antagonist Antibodies as Game-Changers in Treatment of IgA-Driven Autoimmune Disease**
Marjolein van Egmond, PhD, Professor, Oncology and Inflammation, Surgery/Molecular Cell Biology and Immunology, Amsterdam UMC

Multifunctional Antibody-Derived Receptor Agonists for Targeted Immunomodulation
Stefan Zielonka, PhD, Professor, Biomolecular Immunotherapy, Technische Universität Darmstadt

Fc-Engineered Anti-PD-1 for Selective Depletion of Pathogenic T Cells in Autoimmunity
Alexander Rau, PhD, Senior Scientist, Protein Engineering, Anaveon AG

Multibody Engineering for Next-Generation Therapeutic Applications
Yehezkel Sasson, PhD, Senior Vice President, R&D and Technology Development, Biolojic Design Ltd.

BEYOND MABs: RADIOPHARMACEUTICALS

DARPins for Targeted Alpha Therapy: From Promising MP0712 First-in-Human Data to Opportunities for Next Radio-DARPin Candidates
Andreas Bosshart, PhD, Senior Director, Oncology Research, Lead Generation, Molecular Partners AG

Targeting CEACAM5 with Lutetium-177-Conjugated Affibody Molecules
Torbjörn Gräslund, PhD, Professor, Department of Protein Science, KTH Royal Institute of Technology

BEYOND MABs: TARGETED DEGRADATION

Beyond Inhibition: SureTAC for Precision Membrane Protein Removal
Richard Sainson, PhD, CSO, Laigo Bio

A Novel Antibody-Based Targeted Protein Degradation Platform for Immunology Indication
Feng Dong, PhD, Senior Principal Research Scientist, Immunology Discovery, AbbVie Cambridge Research Center

EpiTAC Bispecific Antibodies Degrade Oncogenic Targets to Solve Limitations of Current Clinical Therapeutics
Shyra J. Gardai, PhD, CSO, EpiBiologics

18 NOVEMBER
Biologics for Autoimmune Diseases

PLENARY KEYNOTE SESSION

KEYNOTE PRESENTATION: **The Making of Multispecific Antibodies—A Clinical Perspective**
Roland Kontermann, PhD, Professor & Deputy Head, Biomedical Engineering, University of Stuttgart

KEYNOTE PRESENTATION: **The Future of T Cell Engagers**
Patrick Baeuerle, PhD, Chief Scientific Advisor, Cullinan Therapeutics, Inc.

FIRESIDE CHAT: **Emerging Modalities and the Future of Antibody Engineering**
PANEL MODERATOR:
Jennifer R. Cochran, PhD, Senior Associate Vice Provost for Research and Macovski Professor of Bioengineering, Stanford University
PANELISTS: Patrick Baeuerle, PhD, Chief Scientific Advisor, Cullinan Therapeutics, Inc.
Roland Kontermann, PhD, Professor & Deputy Head, Biomedical Engineering, University of Stuttgart
Ulrike Philippar, PhD, Vice President Oncology, Global Head of Discovery, Johnson & Johnson Innovative Medicine

EMERGING MOAs IN AUTOIMMUNE DISEASE

Dual-Targeting Bispecific Antibodies Broadly Suppress Autoimmune Inflammation by Co-Blocking IL-4Ra and Key Complementary Pathways
Alexey Berezhnoy, PhD, Director, Immunology, Zymeworks

Engineering a TL1A × IL-23 Bispecific Antibody for Dual Cytokine Blockade in IBD
James Ernst, PhD, Executive Director, Xencor, Inc.

FEATURED PRESENTATION: **A New Frontier for the Treatment of Autoimmune Diseases: T Cell Engager Therapies Targeting CD19 or BCMA**
Jennifer Michaelson, PhD, CSO, Cullinan Therapeutics Inc

Characterization of a Biparatopic Sweeping Antibody
Jasmin Sydow-Andersen, PhD, Matrix & Science Lead LMR, Molecular Characterization, Roche Diagnostics GmbH

Targeting IgE via Multiple Novel Mechanisms in IgE Mediated Allergic and Atopic Diseases
Jyothsna Visweswaraiah, PhD, Senior Director, Drug Creation, Seismic Therapeutic

Characterization of a Biparatopic Sweeping Antibody
Jasmin Sydow-Andersen, PhD, Matrix & Science Lead LMR, Molecular Characterization, Roche Diagnostics GmbH

Targeting IgE via Multiple Novel Mechanisms in IgE Mediated Allergic and Atopic Diseases
Jyothsna Visweswaraiah, PhD, Senior Director, Drug Creation, Seismic Therapeutic

ENGINEERED CELL- AND GENE-BASED THERAPIES

TCR Engineered Tregs for Celiac Disease
Yannick Muller, PhD, Assistant Professor, Allergology & Innovative Immunological Therapies, CHUV

Targeting Leukocyte Trafficking Upstream of α4β7: Antagonism of the Cannabinoid GPCR CB2R as a Therapeutic Mechanism in Crohn's Disease
David O'Connell, PhD, Associate Professor, Biomolecular & Biomedical Science, University College Dublin

KEYNOTE PRESENTATION: **A Novel Approach to Enhance Tissue Specific Gene Delivery**
Yang Shen, PhD, Executive Director of Antibody Engineering, Bispecifics, Regeneron

NEXT-GENERATION TARGETS AND DISEASE-SELECTIVE BIOLOGY

SMACk: A Modular Platform for Sterically Masked Activated Cytokines
James T. Koerber, PhD, Distinguished Scientist and Director, Antibody Engineering, Genentech, Inc.

IMC-S118AI: beta-cell Targeted Bispecific for Type 1 Diabetes (T1D) Disease Modification
Tara Mahon, PhD, Associate Director, Protein Science Pipeline, Immunocore Ltd.

19 NOVEMBER
Antibodies Against Challenging Targets

GPCR, ION CHANNEL AND TRANSPORTER TARGETS

SSTR5 Agonist for Post-Bariatric Hypoglycemia
David Felix, PhD, Team Lead, Antibody Discovery, Confo Therapeutics

KEYNOTE PRESENTATION: **Targeting the Adhesion Class of GPCRs with Biologics for Cancer Therapy**
Shohei Koide, PhD, Professor, Biochemistry & Molecular Pharmacology, New York University School of Medicine; Perlmutter Cancer Center, NYU Langone Health

Generating Ion Channel-Modulating Antibodies by Fusing Cysteine-Rich Miniproteins into the Antibody Surface
John D. McCafferty, PhD, CTO and Founder, Maxion Therapeutics

Nanobody Therapy Rescues Behavioural Deficits of NMDA Receptor Hypofunction
Philippe Rondard, PhD, Group Leader, Neuroreceptor Dynamics and Functions, CNRS

STRATEGIES FOR TISSUE- AND COMPARTMENT-SPECIFIC DELIVERY OF BIOLOGICS

Enabling Delivery of Enzyme Replacement Therapies to the Central Nervous System via Transferrin Receptor–Mediated Transport
Cathal Mahon, PhD, Associate Director, Protein Technologies, Denali Therapeutics Inc.

Bispecific Soluble TCR Engagers for T Cell Inhibition
Rodrigo Vazquez-Lombardi, PhD, Co-Founder & CSO, Engimmune Therapeutics AG

PHYSIOLOGICALLY-RELEVANT DISCOVERY AND SCREENING

A "Function-First" Approach to Identify Regulatory T Cell-Targeting Antibodies for Immunotherapy
Mark S. Cragg, PhD, Professor, Experimental Cancer Biology, Antibody and Vaccine Group, School of Cancer Sciences, University of Southampton

Antibodies from Disease-Resilient Individuals: Targeting the Prostaglandin Pathway with Therapeutic Potential for Parkinson's Disease
Sophie Sanford, PhD, Senior Scientist, Alchemab

The Application of Nanodisc Technology Platforms to Develop Therapeutic mAbs for Multi-Pass Transmembrane Protein Target
Donghui Ma, CEO & Founder, DIMA Biotechnology LTD

BISPECIFICS

17 NOVEMBER

Safety and Efficacy of Bispecific and Multispecific Antibodies

ENGINEERING STRATEGIES TO ENHANCE SAFETY AND EFFICACY

Next-Generation Tumour-Targeted Masked Cytokines for Enhanced Tolerability and Localised Anti-Tumour Activity
Alexey Berezhnoy, PhD, Director, Immunology, Zymeworks

Targeting Alternative T Cell Effector Pathways to Enhance the Anti-Tumour Activity of CD3-Engaging Bispecific Antibodies
David J. DiLillo, PhD, Executive Director, Immuno-Oncology, Regeneron Pharmaceuticals

T Cell Engagers Targeting KRAS Mutations
Vipin Suri, PhD, CSO, Clasp Therapeutics

ENA101: A First-in-Class Bispecific T-Cell Engager Targeting a Peptide Derived From Darkfox, a Novel Tumour-Specific Dark Antigen® With Pan-Cancer Expression
Hope Adamson, PhD, Senior Scientist, Protein Engineering, Assay Development, Enara Bio

Safety and Efficacy of T Cell Engagers for the Treatment of Refractory Autoimmune Diseases
Joerg Distler, MD, Director of Rheumatology, Hiller-Research Center, University Hospital Düsseldorf, Heinrich-Heine-University Duesseldorf

TOXICITY MITIGATION AND TRANSLATIONAL MODELING

Elucidating the Structure-PK Relationship of Complex Antibody Formats and Understanding the Underlying Mechanisms for Improved Drug Design
Thomas Kraft, PhD, Subchapter Lead, ADME, Senior Principal Scientist, F. Hoffmann La Roche AG

3D Tumor Microenvironments Enable Mechanistic Profiling of ADCs and Immunomodulatory Antibodies
Giacomo Domenici, PhD, Scientist, Advanced Cell Models for Drug Discovery and Translational Research, iBET Instituto de Biologia Experimental Tecnologica

18 NOVEMBER

Advancing Multispecific Antibodies and Combination Therapy to the Clinic

PLENARY KEYNOTE SESSION

KEYNOTE PRESENTATION: **The Making of Multispecific Antibodies—A Clinical Perspective**
Roland Kontermann, PhD, Professor & Deputy Head, Biomedical Engineering, University of Stuttgart

KEYNOTE PRESENTATION: **The Future of T Cell Engagers**
Patrick Baeuerle, PhD, Chief Scientific Advisor, Cullinan Therapeutics, Inc.

FIRESIDE CHAT: **Emerging Modalities and the Future of Antibody Engineering**
PANEL MODERATOR:
Jennifer R. Cochran, PhD, Senior Associate Vice Provost for Research and Macovski Professor of Bioengineering, Stanford University
PANELISTS: Patrick Baeuerle, PhD, Chief Scientific Advisor, Cullinan Therapeutics, Inc.
Roland Kontermann, PhD, Professor & Deputy Head, Biomedical Engineering, University of Stuttgart
Ulrike Philippar, PhD, Vice President Oncology, Global Head of Discovery, Johnson & Johnson Innovative Medicine

NOVEL ENGINEERING APPROACHES

Engineering of Hypoimmunogenic Biotherapeutics through Precision B Cell Targeting
Dikran Aivazian, PhD, CTO & Head, Research, ADAXION Therapeutics

Antibody-Lectin Chimeras for Glyco-Immune Checkpoint Blockade
Thomas Valerius, MD, Professor, Stem Cell Transplantation & Immunotherapy, Christian Albrechts University of Kiel

Discovery and Development of Click-to-Release ADCs with Enhanced Therapeutic Potential
Lars Guelen, PhD, Head of Protein Development, Tagworks Pharmaceuticals

MAKING MULTISPECIFICS AND MULTIPAYLOAD MOLECULES

KEYNOTE PRESENTATION: **Developability Profiling, off-Target Screening, and CDR Engineering to De-Risk Therapeutic Antibodies**
Arvind Sivasubramanian, PhD, Director, Computational Biology & Platform Technologies, Adimab LLC

Introduction to New-Generation ADCs Based on a First-in-Class Anti-Folate Linker-Drug Platform
Wim H.A. Dokter, PhD, CSO, Byondis B V

DRIVING NOVEL BIOLOGY

T Cell Stimulating Vaccines Empower CD3 Bispecific Antibody Therapy in Solid Tumours
Vitaly Ovcinnikovs, PhD, Senior Scientist, Genmab

T CELL ENGAGERS FOR AUTOIMMUNE DISEASE

T Cell Engagers: Expanding Horizons in Oncology and Beyond
Gulsah Albayrak, PhD, Research Scientist, Department of Oncology, University of Oxford

19 NOVEMBER

Engineering the Next Generation of Bispecific Antibodies

NEXT-GENERATION BI- AND MULTISPECIFICS

Evolve: A Trispecific T Cell Engager with Integrated CD2 Costimulation for the Treatment of Solid and Hematologic Tumours
Jeremy S. Myers, PhD, Senior Vice President, R&D, EvolveImmune Therapeutics Inc.

APPLICATIONS OUTSIDE ONCOLOGY

Bispecific Antibody Shuttles for Cell-Type–Specific CNS Delivery of Proteins and Nucleic Acids
Peter M. Tessier, PhD, Albert M. Mattocks Professor, Pharmaceutical Sciences & Chemical Engineering, University of Michigan

Next-Generation FVIIIa-Mimetic Bispecific Antibody NXT007 for Hemophilia A: Evaluation in Preclinical Models
Matthew Locke, PhD, Principal Scientist, Non-Malignant Hematology, Roche

Dual Targeting of Transferrin Receptor and CD98hc Enhances Brain Exposure of Large Molecules
Padma Akkapeddi, PhD, Senior Scientist, Antibody Discovery & Protein Engineering, Denali Therapeutics, Inc.

NOVEL APPROACHES IN ONCOLOGY

KEYNOTE PRESENTATION: **Tumour-Selective CD47 Targeting for the Treatment of Platinum-Resistant Ovarian Cancer**
Nicolas Fischer, PhD, CEO, Light Chain Bioscience

Comparative Analysis of 4-1BB and CD28 Tumour-Targeted Co-Stimulation to Support T Cell Bispecific Antibody Therapy in Solid Tumours
Teemu T. Junttila, PhD, Principal Scientist, Translational Oncology, Genentech

Leveraging Single-Cell Technologies to Engineer the Immune System
Ido Amit, PhD, Principal Investigator, Director, Weizmann Immunotherapy Center, Weizmann Institute of Science

***In vivo* mRNA-Encoded T Cell Engagers**
Wei Xu, PhD, CSO, Metistech Bio

Precision-Activated T Cell Engagers in Immuno-Oncology: Pharmacological Characterisation of Albumin-Masked TCR Multispecific VHHs
Christelle Nonne, PhD, Senior Principal Scientist, LMR, Sanofi Group

IMMUNOTHERAPY

17 NOVEMBER

T Cell Engagers

CONDITIONALLY ACTIVATED TCEs FOR SAFER SOLID TUMOUR TARGETING

Enhancing Safety to Unlock Efficacy: A Novel Class of Conditionally-Activated TCEs for Solid Tumours
Aude Segaliny, PhD, Vice President, Research & Development, Amberstone Biosciences

PRO-XTEN Masked T cell Engagers; A Novel Therapeutic Approach Enabling Protease-Specific Activation of TCEs Only in the Tumour Microenvironment to Mitigate Damage to Healthy Tissues and Reduce Toxicity
Volker Schellenberger, PhD, Senior Vice President, Research Oncology, Vir Biotechnology, Inc.

A Conditionally-Activ©, Dual-Targeting BiTAC-TCE with Superior Tumour Selectivity for the Treatment of Solid Tumours
Steffen Dickopf, PhD, Director, Immuno Oncology, VERAXA Biotech GmbH

BA3182, a Dual-Conditionally Active Biologic (CAB) EpCAM x CD3 Bispecific T Cell Engager in Patients with Treatment Refractory Metastatic Adenocarcinoma
Kartika Aysola, Exec Dir & Head, Medical Affairs, BioAtla Inc

Antengene's ATG-201, a Differentiated, Masked CD-19 Targeting Bispecific TCE
Jay M Mei, Founder & CEO, Antengene Corp

TCE ENGINEERING: CO-STIMULATION, GATING AND EFFECTOR BIAS

TriTCE Co-Stim: A Differentiated T Cell Engager Platform with Conditional cis CD28 Co-Stimulation and Transferability to Diverse Targeting Strategies
Nina E. Weisser, PhD, Director, Multispecific Antibody Therapeutics, Zymeworks, Inc.

MP0632, an AND-Gated Switch-DARPin T Cell Engager with CD2 Costimulation for Ovarian Cancer
Marcela Guzman Ayala, PhD, Head of In Vitro Pharmacology, Molecular Partners

Engineering Affinity Attenuated and Effector CD8 Biased T Cell Engagers
Christopher Lloyd, PhD, Director, Biologics Engineering, AstraZeneca

MAXIMISING TCE EFFICACY

Turning Cold Tumours Hot: Dual-Modality Strategies to Boost T Cell Engagers in Solid Tumours
Abdullah Elsayed, PhD, Group Leader, Bispecific Antibody Research, Philochem AG

Maximising the Power of Bispecific Therapies for Treating Solid Tumours
Tatjana Petojevic, PhD, Director, Protein Sciences, Rondo Therapeutics

18 NOVEMBER

Advances in Immunoengineering

PLENARY KEYNOTE SESSION

KEYNOTE PRESENTATION: **The Making of Multispecific Antibodies—A Clinical Perspective**
Roland Kontermann, PhD, Professor & Deputy Head, Biomedical Engineering, University of Stuttgart

KEYNOTE PRESENTATION: **The Future of T Cell Engagers**
Patrick Baeuerle, PhD, Chief Scientific Advisor, Cullinan Therapeutics, Inc.

FIRESIDE CHAT: **Emerging Modalities and the Future of Antibody Engineering**
PANEL MODERATOR: Jennifer R. Cochran, PhD, Senior Associate Vice Provost for Research and Macovski Professor of Bioengineering, Stanford University
PANELISTS: Patrick Baeuerle, PhD, Chief Scientific Advisor, Cullinan Therapeutics, Inc.
Roland Kontermann, PhD, Professor & Deputy Head, Biomedical Engineering, University of Stuttgart
Ulrike Philippar, PhD, Vice President Oncology, Global Head of Discovery, Johnson & Johnson Innovative Medicine

ENGINEERING NEXT-GEN CAR T CELLS

KEYNOTE PRESENTATION: **Engineering More Effective CAR T Cells by Coopting T Cell Signaling Networks**
Robbie G. Majzner, MD, Dana Farber Cancer Institute

Reshaping Adoptive T Cell Therapies with T Memory Cell–Based Strategies, Control of Graft-Versus-Host Disease (GVHD), and Modulation of the Tumor Microenvironment (TME)
Thomas Boeldicke, PhD, Project Leader, Structure & Function of Proteins, Helmholtz Center for Infection Research

Novel Orthogonal Receptor Platform Activating the IL12 Pathway in CAR-T Cells Using a Small-Molecule Ligand
Dominic Schwarz, Graduate Student, Chemistry & Pharmacy, Ludwig Maximilians Univ

IN VIVO PROGRAMMING, DELIVERY & CONTROL OF ENGINEERED CELL THERAPIES

Could *in vivo* CAR T Cell Therapy Replace *ex Vivo*?
Adrian Bot, MD, PhD, Former CSO, Executive Vice President, R&D, Capstan Therapeutics

Engineering Armoured *in vivo* CAR T Cells through Targeted Delivery and Transient mRNA Gating
Shimobi Onuoha, PhD, CTO, Chimeris UK Ltd.

***In vivo* Control of CAR Ts with Drug-Responsive Protein Switches Engineered by Directed Evolution**
Michael Traxlmayr, PhD, Group Leader, BOKU University

Increasing the Safety of Non-Viral Gene Transfer by Sleeping-Beauty Modification
Katrin Mestermann, PhD, Scientific Project Manager, Fraunhofer Institute for Cell Therapy & Immunology IZI

A Novel Polymeric Gene Delivery Platform to Precisely Target and Reprogram Cells *in vivo* for Hematological Malignancies and Beyond
Cecile Bauche, PhD, CSO and Co-Founder, Alaya.bio

ENGINEERING MULTISPECIFIC AND TCR-DIRECTED IMMUNE ENGAGERS

ML Guided Design of Multi-Specific Immune Cell Engagers
Simon Bornschein, CEO, Coding Bio

TCR Constant Region-Targeting VHH Bispecifics: An NHP Cross-Reactive Alternative to CD3 T-Cell Engagers
Michael B. Battles, PhD, Principal Scientist, Adimab, LLC

Engineering Novel TCR-Mimic Antibody-Based T Cell Engagers to Target the Intracellular Proteome for the Treatment of Solid Tumors
Dongxing Zha, PhD, CEO, Ypsilon Therapeutics

19 NOVEMBER

Next-Generation Immunotherapies

TCR AND BISPECIFIC APPROACHES FOR SOLID TUMOURS

KEYNOTE PRESENTATION: **Targeting PRAME+ Cancers: Clinical Progress across TCR T Cell Therapy and Bispecific Approaches**
Paul Peter Tak, MD, PhD, FMedSci, President & CEO, Candel Therapeutics

LGTX-101: A Novel Machine-Learning-Derived, Selectivity-Enhanced Nectin-4 x CD3 Bispecific T Cell Engager Mitigates On-Target and Off-Tumour Toxicity Associated with Nectin-4 Targeting
Angus M. Sinclair, PhD, CSO, Preclinical R&D, LabGenius Therapeutics

XCR1+ Dendritic Cell (DC) Role in Anti-Tumoural Response to Anti PD-L1 Antibody: Data from the Phase Ib/II Trial of DC Vaccination in Small Cell Lung Cancer Patients
Maria Gonzalez Cao, PhD, Chair, Melanoma Medical Oncology Unit, Oncology Institute Dr Rosell, Dexeus University Hospital

BEYOND CHECKPOINT: REPROGRAMMING ANTITUMOUR IMMUNITY

Leveraging TNFR for Antitumour Immunity: Treg Depletion and Myeloid Reprogramming Versus T Cell Co-Stimulation
Björn L. Frendeus, PhD, CSO, BioInvent International AB

AZD6750: Design and Efficacy of a CD8-Guided IL-2 that Enhances CD8+ T Cell Function
Aidan Riley, PhD, Assoc Director, Biologics Engineering (Early Oncology), AstraZeneca

Updates on Clinical Trials with AB248 and AB821, CD8-selective IL-2 and IL-21 Cytokines
Ivana Djuretic, PhD, Founder & CSO, Asher Biotherapeutics

Multimodal Biological Immunotherapy for Solid Tumours: Aglatimagene Besadenovec (CAN-2409)
Paul Peter Tak, MD, PhD, FMedSci, President & CEO, Candel Therapeutics

CHECKPOINT INHIBITORS—LESSONS FROM THE CLINIC

Immune Checkpoint Inhibitor Therapies: Building on the Revolution to Improve Patient Outcomes
Hardev S. Pandha, Honorary Professor, Urological Oncology, University of Surrey

Phase Ib/II Study of Neoadjuvant Cemiplimab Plus Imiquimod and Laser Therapy in High-Risk Resectable Basal Cell Carcinoma
Maria Gonzalez Cao, PhD, Chair, Melanoma Medical Oncology Unit, Oncology Institute Dr. Rosell, Dexeus University Hospital

B Cells and Antibodies in Melanoma: Emerging Biomarkers to Predict Checkpoint Inhibitor Toxicity and Response
Sophia N. Karagiannis, PhD, Professor, Translational Cancer Immunology & Immunotherapy, Kings College London

CLINICAL OUTCOMES IN IMMUNOTHERAPEUTICS

PANEL DISCUSSION: Clinical Outcomes in Immunotherapy—Where Are We Now?
PANEL MODERATORS:
David Cole, Head of Research, Accession Therapeutics Inc.; Honorary Professor, Cardiff University
Björn L. Frendeus, PhD, CSO, BioInvent International AB
PANELISTS:
Cedrik M Britten, CMO, Immatics Biotechnologies GmbH
Maria Gonzalez Cao, PhD, Chair, Melanoma Medical Oncology Unit, Oncology Institute Dr. Rosell, Dexeus University Hospital
Hardev S. Pandha, Honorary Professor, Urological Oncology, University of Surrey
Paul Peter Tak, MD, PhD, FMedSci, President & CEO, Candel Therapeutics

ANALYTICAL

17 NOVEMBER

Optimisation & Developability

COMPUTATIONAL TOOLS AND ML-DRIVEN BIOLOGICS OPTIMISATION

Practical, Scalable Structure Based Modelling for Rational Engineering of Multispecifics
Saeed Izadi, PhD, Senior Principal Scientist & Group Leader, Pharmaceutical Development, Genentech, Inc.

***In silico* Approaches for siRNA AOC Optimisation**
Josephine Alba, PhD, Senior Expert I Data Science, Biologics Research Center, Novartis Pharma AG

Machine Learning for Lead Optimisation Workflow (MeLLOw): Integrating *in silico* and Wet Lab Data for Biologics Engineering
Owen Vickery, PhD, Associate Principal Scientist, Augmented Biologics, AstraZeneca

Multi-Objective Antibody Optimisation with Property Enhancer (PropEn)
Vladimir Gligorijević, PhD, Senior Director, AI/ML Prescient Design, Genentech

Modelling Biparatopic Antibody Target Engagement and Pharmacology
James Lodge, Senior Scientist, Large Molecule Research, GSK

DEVELOPABILITY & DRUG READINESS

KEYNOTE PRESENTATION: **Predictive Strengths and Critical Gaps in Next-Generation Developability Workflows**
Hristo Svilenov, PhD, Associate Professor, TUM

From Molecules to Drug Readiness
Tobias Grosskopf, PhD, Leader, F Hoffmann La Roche AG

Optimisation of Tailor-Made Interleukin-2 Engineered Versions for Therapy: Handling Functional Complexity and Developability Issues of a Challenging Molecule
Gertrudis Rojas, PhD, Senior Scientist and Head, Protein Engineering and Computational Biology, Center of Molecular Immunology

Ensuring Manufacture of Next Generation Biopharmaceuticals by Developability (EMBeDs)
David J. Brockwell, PhD, Professor, School of Molecular and Cellular Biology, University of Leeds

18 NOVEMBER

Analytical Characterisation of Biotherapeutics

PLENARY KEYNOTE SESSION

KEYNOTE PRESENTATION: **The Making of Multispecific Antibodies—A Clinical Perspective**
Roland Kontermann, PhD, Professor & Deputy Head, Biomedical Engineering, University of Stuttgart

KEYNOTE PRESENTATION: **The Future of T Cell Engagers**
Patrick Baeuerle, PhD, Chief Scientific Advisor, Cullinan Therapeutics, Inc.

FIRESIDE CHAT: **Emerging Modalities and the Future of Antibody Engineering**
PANEL MODERATOR:
Jennifer R. Cochran, PhD, Senior Associate Vice Provost for Research and Macovski Professor of Bioengineering, Stanford University
PANELISTS: Patrick Baeuerle, PhD, Chief Scientific Advisor, Cullinan Therapeutics, Inc.
Roland Kontermann, PhD, Professor & Deputy Head, Biomedical Engineering, University of Stuttgart
Ulrike Philippar, PhD, Vice President Oncology, Global Head of Discovery, Johnson & Johnson Innovative Medicine

STRUCTURAL AND BIOPHYSICAL ANALYTICS FOR COMPLEX MODALITIES

KEYNOTE PRESENTATION: **Structural Biology at the Forefront of Biotherapeutics: Cryo-EM, AI, and Complex Modalities**
Alexey Rak, PhD, Head, Biostructure and Biophysics, Sanofi, France

Strategy for Evaluating Undesired Mis-Paired Variants across Bispecific Antibody Modalities
Maki Yoshida, Deputy Head, Analytical Development Dept, Pharmaceutical Technology Div, Chugai Pharmaceutical Co., Ltd.

Characterisation of Bacterial Glycoconjugate Vaccines by Liquid Chromatography—Mass Spectrometry
Anabel Torrente Lopez, PhD, Postdoc Researcher, Center for Proteomics and Metabolomics, Leiden University Medical Center

From Suspension to Signal: Enabling Analytical Characterisatino of Therapeutic Proteins in High-Dose Non-Aqueous Suspension Formulations
Arnelle Loebbert, PhD, Novartis

Thermal Unfolding: From Heuristic Interpretation to Quantitative Models
Paul Molinaro, PhD, Postdoc Research Fellow, Biotherapeutic Dev, Boehringer Ingelheim Pharma GmbH & Co KG

FUNCTIONAL, POTENCY, AND CELL-BASED ASSAYS

Design of Potency Assays in Development of Biologics
Petr Obrdlik, PhD, Lab Head Early Analytical Development, R&D, Novartis Biologics, Switzerland

High-Throughput Automation Platform for Miniaturised Biophysical Assays: Accelerating Compound Screening with One Click
Gonçalo Silva, Senior Research Scientist, Biophysics & Injectable Formulation 1, Novo Nordisk A/S

Decoding Macrophage-Fibroblast Cross-Talk to Enable Next Generation Anti-Fibrotic Therapies
Daniel M. Simão, PhD, Head, Bayer Pharma Satellite Lab, iBET Instituto de Biologia Experimental Tecnologica

AI INTEGRATION IN ANALYTICAL CHARACTERISATION

AI-Based Analysis of Label-Free Live Cell Imaging of T Cell Mediated Tumour Killing Assay Enables Competitive and Robust Hit Calling
Josefa dela Cruz-Chuh, Scientist 4, Biochemical and Cellular Pharmacology (BCP), Genentech

Natural Antibody Evolution, Human Expertise, and AI: The MAb-Intelligence Triad for Next-Generation Antibody Discovery
Casper Marsman, Sr Scientist, B Cell Platform, Kling Biotherapeutics BV

19 NOVEMBER

Protein Stability & Formulation

BIOPHYSICAL STABILITY AND AGGREGATION

KEYNOTE PRESENTATION: **What Have We Learned from a Decade of Research into Polysorbate Degradation?**
Patrick Garidel, PhD, Head, Process, Purification and Pharma Development, Biopharma, Boehringer Ingelheim Pharma GmbH, Germany

Decoding Photodegradation of ADC Payloads: Integrating *In Silico* Modelling with Experimental Evidence to Understand and Predict Stability
Giuseppe L. Licari, PhD, Lead Scientist, Computational Structural Biology, Global Drug Product Development—BDC, Merck Serono SA

A Multiplexed Approach to Protein Aggregation: Resolving Heterogeneity from Particles to Interfaces
Vito Foderà, PhD, Professor, Biophysics, University of Copenhagen

Insights into Fab Nebulisation: How to Minimise Aggregates for Inhaled Biologics
Marlon Hinner, PhD, Group Leader, Roche

Colloidal Stability Prediction of Multivalent NANOBODY Molecules Using Machine Learning
Eric Lorent, PhD, Principal Scientist, Sanofi

Optimising Colloidal Stability and Viscosity of Multispecific Antibodies at the Drug Discovery-Development Interface: A Systematic Predictive Case Study
Goran Miličić, PhD, Senior Expert, Science & Technology, Novartis

NOVEL DELIVERY AND FORMULATION STRATEGIES

Molecular Dynamics Analysis toward Understanding Formulation Dependent DSC Behavior of Antibodies
Kota Yamaguchi, Research Scientist, Formulation Research, Injectable Technologies, Chugai Pharmaceutical Co Ltd.

UTAC: Engineering a Bispecific that Converts Clinical Antibodies into Oral Formulations Using Active Retro-Transcytosis
Maurits F Kleijnen, PhD, Head, Research, Intract Pharma Ltd.

Beyond PEGylation: INCYPRO-Stabilisation of Asparaginase Enables Long Acting Enzyme Therapy for Acute Lymphoblastic Leukemia
Saskia Neubacher, PhD, CSO, R&D, Incircular B.V.

Bayesian Optimisation for Efficient Multi-Objective Formulation Development of Biologics
Isabel Waibel, Graduate Student, Biochemical Engineering, ETH Zurich

17 NOVEMBER

Leveraging Data Science for Enhanced Protein Expression

INTEGRATING DATA PIPELINES TO ENABLE FASTER DATA-DRIVEN DECISIONS

FEATURED SPEAKER: A Structured Framework for Capturing Protein Expression and Purification Data to Develop Foundation-Machine-Learning Models
Nicola Burgess-Brown, PhD, Professorial Research Fellow, UCL, London; COO, Protein Sciences, Structural Genomics Consortium

IVTT-Accelerated Protein Discovery: Generating Fit-for-Purpose AI Training Data
Frederikke Bjergvang Flagstad, Senior Automation Scientist, Cross Modality Workflows, Novo Nordisk AS

Building the Protein Lab of the Future at AstraZeneca: Automation First Science and AI Ready Data at Scale
Stanislas Blein, PhD, Senior Director and Head of Protein Sciences & Analytics, AstraZeneca

DECODING GENETIC RULES TO BOOST EXPRESSION

High-Throughput Biophysical Data Generation as the Missing Link in AI-Driven Protein Design
Nikolay Dobrev, PhD, Founder & CEO, Data Powered Therapeutics GmbH

From Data Science to Fine-Tuning Codon Optimization for High-Yield Protein Production in *E. coli*
Greg Boel, PhD, Principal Investigator, CNRS

Deep Mutational Learning for the Precision Engineering of Enzymes and Biosensors
Alperen Dalkiran, PhD, Postdoctoral Research Associate, School of Informatics, University of Edinburgh

AI-Driven Design for Producing *de Novo* Designed Miniproteins
James Bowman, PhD, CTO, AI Proteins

18 NOVEMBER

Designing High-Performance Expression Platforms

PLENARY KEYNOTE SESSION

KEYNOTE PRESENTATION: The Making of Multispecific Antibodies—A Clinical Perspective
Roland Kontermann, PhD, Professor & Deputy Head, Biomedical Engineering, University of Stuttgart

KEYNOTE PRESENTATION: The Future of T Cell Engagers
Patrick Baeuerle, PhD, Chief Scientific Advisor, Cullinan Therapeutics, Inc.

FIRESIDE CHAT: Emerging Modalities and the Future of Antibody Engineering
PANEL MODERATOR:
Jennifer R. Cochran, PhD, Senior Associate Vice Provost for Research and Macovski Professor of Bioengineering, Stanford University
PANELISTS: Patrick Baeuerle, PhD, Chief Scientific Advisor, Cullinan Therapeutics, Inc.
Roland Kontermann, PhD, Professor & Deputy Head, Biomedical Engineering, University of Stuttgart
Ulrike Philippar, PhD, Vice President Oncology, Global Head of Discovery, Johnson & Johnson Innovative Medicine

SELECTING, ENGINEERING, AND OPTIMISING HOSTS

Automated CHO Cell Engineering: Diagnosing and Resolving Biosynthetic Bottlenecks in <4 weeks
Adam Brown, Professor of Biopharmaceutical Engineering, University of Sheffield; Co-Founder, Silvia Bio and Syngensys

Methods and Technologies for Customisable Protein Expression in CHO Cells
Lindsey Pearson, PhD, Senior Scientist, Protein and Cellular Sciences, GSK

RMCE-Enabled Genome-Wide CRISPR Screening for High-Performance CHO Cell Engineering
Gyun Min Lee, PhD, Professor, Graduate School of Engineering Biology, KAIST

Integrating Genome-Wide CRISPR Screening and Host Cell Engineering in HeLaS3 Producer Lines for rAAV Production
Filipa A Moura, Research Scientist, iBET Instituto de Biologia Experimental Tecnologica

PURExpress—The Rebuilt Protein Factory
Takashi Ebihara, COO, GeneFrontier Corp.

ENHANCING EXPRESSION: COMPLEX PROTEINS

Metabolic Shutdown in Bacteria—New Prospects for Antimicrobials
Rivka Isaacson, PhD, Professor of Molecular Biophysics, Department of Chemistry, King's College London

ENHANCING EXPRESSION: PROTEIN COMPLEXES

Robust TCR Production for the Structural Study of TCR-pMHC Complexes
Leire Oyon, Research Scientist, Protein Crystallography Unit, Navarrabiomed

Robust Production of Virus-Like Particles in HEK293 Cell Lines
Alfred M. Engel, PhD, Teamlead, Cell Culture Technology, Roche Diagnostics GmbH

From BacMam to Breakthrough: REMBAC for Tunable Expression and Stable Cell Line Engineering
Manuel Reithofer, PhD, Department of Biotechnology and Food Science, Institute of Molecular Biotechnology, BOKU University

Development of an Orthoflavivirus-Like Particle (Orthoflavi-VLP) Pipeline for Therapeutic and Diagnostic Applications
Luca Schelle, PhD, Researcher, Immunology & Infection & Pandemic Research IIP, Fraunhofer ITMP

A Molecular Playground: Building Virus-Like-Particles in Insect Cells
Maren Schubert, PhD, Junior Research Group Leader, Virus-Like-Particle Based Technologies, Helmholtz Center for Infection Research

19 NOVEMBER

Highly Parallel Protein Discovery Workflows

INTEGRATING PRODUCTION, PURIFICATION, AND CHARACTERISATION WORKFLOWS

Considerations for Integrating Workflows for Protein Production and Characterisation to Enable Quality Data Generation for Building ML Models
Christopher Cooper, DPhil, Senior Lecturer in Biotechnology, University of Surrey

Advanced Bioanalytics for Comprehensive Characterisation of Biotherapeutics Manufacturing
Sofia B. Carvalho, PhD, Principal Scientist, Animal Cell Technology, Instituto de Biologia Experimental Tecnologica (iBET)

Decoding mAb Expression in CHO Cells through High-Throughput Screening Strategies
Jesús Lavado García, PhD, Postdoctoral Researcher, Co-PI of Mammalian Cell and Bioprocess Engineering Group, Novo Nordisk Foundation Center for Biosustainability

Purifying Challenging Multi-Protein Complexes for Structural Studies: Recombinant Expression vs Purification of Endogenous Complexes from Engineered Cell Lines
Arnaud Poterszman, PhD, Research Director, Integrated Structural Biology, IGBMC

PARALLEL PREDICTIVE WORKFLOWS TO SCALE BIOPRODUCTION

From BacMam to Breakthrough: REMBAC for Tunable Expression and Stable Cell Line Engineering
Manuel Reithofer, PhD, Department of Biotechnology and Food Science, Institute of Molecular Biotechnology, BOKU University

An Integrated End-to-End Workflow for the Production of Drug-Like Multispecific Therapeutic Antibodies
Cyrille Dreyfus, PhD, Associate Director & Head, Antibody Engineering, Protein Sciences, Ichnos Glenmark Innovation

From Discovery to Manufacturing: Enabling Predictive Bioprocessing for Scalable Biologics
Matthias Müllner, PhD, CEO & Co-Founder, Bespark Bio GmbH

Miniaturisation-Driven Acceleration of Expression and Screening Workflows
Maurine Fleury, Bioproduction Manager, Production Platform, Affilogic

MACHINE LEARNING

Training SEMINARS
By Cambridge Healthtech Institute

16 NOVEMBER

TS3A: Introduction to Machine Learning for Biologics Design

Christopher R. Corbeil, PhD, Research Officer, Human Health Therapeutics, National Research Council Canada

17 NOVEMBER

TS7B: AI-Driven Design of Biologics: A Hands-on Guide to Using State-of-the-Art ML Protein Models

David P. Nannemann, PhD, Vice President, Rosetta Commons Foundation

18 NOVEMBER

Machine Learning for Protein Engineering Part 1

PLENARY KEYNOTE SESSION

KEYNOTE PRESENTATION: **The Making of Multispecific Antibodies—A Clinical Perspective**
Roland Kontermann, PhD, Professor & Deputy Head, Biomedical Engineering, University of Stuttgart

KEYNOTE PRESENTATION: **The Future of T Cell Engagers**
Patrick Baeuerle, PhD, Chief Scientific Advisor, Cullinan Therapeutics, Inc.

FIRESIDE CHAT: **Emerging Modalities and the Future of Antibody Engineering**
PANEL MODERATOR:
Jennifer R. Cochran, PhD, Senior Associate Vice Provost for Research and Macovski Professor of Bioengineering, Stanford University
PANELISTS: Patrick Baeuerle, PhD, Chief Scientific Advisor, Cullinan Therapeutics, Inc.
Roland Kontermann, PhD, Professor & Deputy Head, Biomedical Engineering, University of Stuttgart
Ulrike Philippar, PhD, Vice President Oncology, Global Head of Discovery, Johnson & Johnson Innovative Medicine

ADVANCING MINI BINDERS TO THE CLINIC

Programmable Molecule Design with Discrete Generative Models
Pranam Chatterjee, PhD, Assistant Professor, Bioengineering, University of Pennsylvania

Generation of a Massive Dataset on VHH:antigen Stability Via High-throughput (DMS) Experiments

Samuel Demharter, PhD, Senior Data Scientist, Discovery Data Science and Protein Science & Technologies, Genmab

KEYNOTE PRESENTATION: **Disulphide and Sequence-encoded Conformational Priors Guide Nanobody Structure Prediction**
Pietro Sormanni, PhD, Associate Professor & Royal Society University Research Fellow, Department of Chemical Engineering, Imperial College London

AI DESIGN FOR MULTISPECIFICS AND COMPLEX BIOLOGICS

AI-Designed Multi-specific ADCs in Standard IgG Format
Tzvika Hartman, PhD, Senior Vice President, Computational, Biolojic Design Ltd.

Stability Prediction for Multispecific Antibodies
Roberto Spreafico, PhD, Senior Director, Biologics AI Innovation, AstraZeneca

BENCHMARKING ML MODELS

Validation and Analysis of 12,000 AI-driven CAR-T Designs in the Bits to Binders Competition
Clay Kosonocky, Researcher, Molecular Biosciences, University of Texas at Austin
Large-Scale Benchmarking of Generative Models for De Novo Antibody Design
Natasha Murakowska, PhD, Director, Applied Data Science, A-Alpha Bio

INTELLECTUAL PROPERTY AND COLLABORATIVE DATA

The Future of Antibody Patenting: How do AI, Court Decisions, and New Paratope Mapping Technologies Affect Patenting Strategies?
Ulrich Storz, PhD, Senior Partner, Michalski-Hüttermann & Partner

The Importance of Federated Networks for Antibody AI Applications
Robin Roehm, PhD, CEO & Co-Founder, Apheris

19 NOVEMBER

Machine Learning for Protein Engineering Part 2

PANEL DISCUSSION: Generation of AI-Based Therapeutics
PANEL MODERATOR:
Andrew Buchanan, PhD, FRSC, Head of Discovery, Stealth Mode Biotech
PANELISTS:
Simon Kohl, PhD, Founder and CEO, Latent Labs
Jinwoo Leem, DPhil, Senior Machine Learning Research Scientist, Isomorphic Labs
Talip Uçar, Founding Member, Boltz

DE NOVO DESIGN OF PROTEIN THERAPEUTICS: TECHNOLOGY ADVANCES MEET REAL-WORLD APPLICATIONS

AI for Biologics: Transition from Discovery to Design
Yu Qiu, PhD, Executive Director, Biologics Design and Technology, AstraZeneca

De novo VHH Design in Practice: Bridging AI Innovation with Real-World Biologics Design
Norbert Furtmann, PhD, Head, Biologics AI & Design, Large Molecules Research, Sanofi

FROM STRUCTURE PREDICTION TO DE NOVO VACCINE DESIGN

Structural Plausibility without Binding Specificity: Limits of AI-Based Antibody-Antigen Structure Prediction Confidence Scores
Eva Smorodina, PhD, Computational Structural Biologist, University of Oslo

Directed Evolution Informs Divergent Pathways of Antibody Affinity Maturation
Daniel Bader, Graduate Student, Scripps Research Institute

AGENTIC AI AND SELF-DRIVING LABS FOR BIOLOGICS DISCOVERY

An AI-Powered Biofoundry for Protein Discovery and Engineering
Huimin Zhao, PhD, Steven L. Miller Chair Professor, University of Illinois Urbana Champaign

Automating Biological Science
Ross D. King, PhD, Professor, Chemical Engineering & Biotechnology, University of Cambridge

Integrating Physics & Deep Learning for Antibody Design
Joost Schymkowitz, PhD, Professor & Group Leader, Switch Lab, VIB-KU Leuven

THERAPEUTICS

17 NOVEMBER

Antibody-Based Therapies

ANTIBODIES TO WATCH

Antibodies to Watch in 2027
Silvia Crescioli, PhD, Independent Consultant

NEXT-GENERATION ANTIBODY MODALITIES FOR IMMUNOMODULATION

KEYNOTE PRESENTATION: **Unlocking New Horizons: Anti-CD89 Antagonist Antibodies as Game-Changers in Treatment of IgA-Driven Autoimmune Disease**
Marjolein van Egmond, PhD, Professor, Oncology and Inflammation, Surgery/Molecular Cell Biology and Immunology, Amsterdam UMC

Multifunctional Antibody-Derived Receptor Agonists for Targeted Immunomodulation
Stefan Zielonka, PhD, Professor, Biomolecular Immunotherapy, Technische Universität Darmstadt

Fc-Engineered Anti-PD-1 for Selective Depletion of Pathogenic T Cells in Autoimmunity
Alexander Rau, PhD, Senior Scientist, Protein Engineering, Anaveon AG

Multibody Engineering for Next-Generation Therapeutic Applications
Yehezkel Sasson, PhD, Senior Vice President, R&D and Technology Development, Biolojic Design Ltd.

BEYOND MABs: RADIOPHARMACEUTICALS

DARPins for Targeted Alpha Therapy: From Promising MP0712 First-in-Human Data to Opportunities for Next Radio-DARPin Candidates
Andreas Bosshart, PhD, Senior Director, Oncology Research, Lead Generation, Molecular Partners AG

Targeting CEACAM5 with Lutetium-177-Conjugated Affibody Molecules
Torbjörn Gräslund, PhD, Professor, Department of Protein Science, KTH Royal Institute of Technology

BEYOND MABs: TARGETED DEGRADATION

Beyond Inhibition: SureTAC for Precision Membrane Protein Removal
Richard Sainson, PhD, CSO, Laigo Bio

A Novel Antibody-Based Targeted Protein Degradation Platform for Immunology Indication
Feng Dong, PhD, Senior Principal Research Scientist, Immunology Discovery, AbbVie Cambridge Research Center

EpiTAC Bispecific Antibodies Degrade Oncogenic Targets to Solve Limitations of Current Clinical Therapeutics
Shyra J. Gardai, PhD, CSO, EpiBiologics

18 NOVEMBER

Engineering Next-Generation Conjugates

PLENARY KEYNOTE SESSION

KEYNOTE PRESENTATION: **The Making of Multispecific Antibodies—A Clinical Perspective**
Roland Kontermann, PhD, Professor & Deputy Head, Biomedical Engineering, University of Stuttgart

KEYNOTE PRESENTATION: **The Future of T Cell Engagers**
Patrick Baeuerle, PhD, Chief Scientific Advisor, Cullinan Therapeutics, Inc.

FIRESIDE CHAT: **Emerging Modalities and the Future of Antibody Engineering**
PANEL MODERATOR:
Jennifer R. Cochran, PhD, Senior Associate Vice Provost for Research and Macovski Professor of Bioengineering, Stanford University
PANELISTS:
Patrick Baeuerle, PhD, Chief Scientific Advisor, Cullinan Therapeutics, Inc.
Roland Kontermann, PhD, Professor & Deputy Head, Biomedical Engineering, University of Stuttgart
Ulrike Philippar, PhD, Vice President Oncology, Global Head of Discovery, Johnson & Johnson Innovative Medicine

ENGINEERING COMPLEX SCAFFOLDS AND DELIVERY FORMATS

KEYNOTE PRESENTATION: **Beyond Classical ADCs: Designing Next-Generation Conjugates for Precision, Tumour Uptake, and Therapeutic Index**
Rakesh Dixit, PhD, DABT, CEO & President, Bionavigen Oncology, LLC; CSO, TMAB Therapeutics, Regio Biosciences

Engineering a Fast-Clearing Protein Drug Conjugate for Enhanced Tumor Selectivity and Reduced Off-Tumor Toxicity
Joseph F. Nabhan, PhD, CSO, K2B Therapeutics

Smaller ADC Formats Based on TheranoStick Technology Could Make the Difference for Solid Tumors
Meddy El Alaoui, PhD, CEO, AbTx

Unlocking the Potential of Bispecific Conjugates through Target Pair Discovery
Arne Scheu, PhD, CEO, Valink Therapeutics Ltd.

THE NEXT GENERATION OF CONJUGATED PAYLOADS

A Novel Degrader Antibody Conjugate for the Treatment of ADC-Resistant Cancers
Joost Uitdehaag, PhD, Head of Biology, Crossfire Oncology

Identification of Novel Payloads and Payload Combinations for Next Generation ADCs
Tara Arvedson, PhD, CSO, Hexagon Bio

Targeted Protein Alkylation as an Emerging ADC Payload Modality: Preclinical Profile of the B7H3 ADC IKS073
Jutta Deckert, PhD, Vice President, Research & Development, Iksuda Therapeutics

19 NOVEMBER

Novel Peptide Drug Discovery

DELIVERY OF PEPTIDE THERAPEUTICS

Intracellular Delivery of Proteome-Modulating Peptides and Proteins
Chris Alabi, PhD, Fred H. Rhodes Professor of Engineering, Cornell University

Targeting Peptides for Enhanced Tissue Delivery
Elise Bernard, PhD, Associate Principal Scientist, AstraZeneca

Transmucosal Peptide Delivery
Maria Jose Alonso, PhD, Professor, Biopharmaceutics & Pharmaceutical Technology, University of Santiago de Compostela

RATIONAL *DE NOVO* DESIGN AND LIBRARY-BASED DISCOVERY

KEYNOTE PRESENTATION: **Real-World Progress, Challenges, and Opportunities for AI in Protein and Peptide Discovery**
Peter Clark, PhD, Vice President, Computational Drug Design, Novo Nordisk Inc.

FEATURED PRESENTATION: **Developing Membrane-Permeable Cyclic Peptides for Targeting Intracellular Proteins and for Oral Applications**
Christian Heinis, PhD, Associate Professor, Lab of Therapeutic Proteins & Peptides, EPFL Lausanne

IMMUNOCYTOKINES AND IMMUNOCONJUGATES

Fluorination as a Molecular Design Parameter for Programming Peptide Nanocarriers
Beate Koksch, PhD, Professor, Organic Chemistry, Freie Universität Berlin

Platforms for the Intracellular Generation and High-Throughput Screening of Cyclic Peptide Libraries
Ali Tavassoli, PhD, Professor of Chemical Biology

***De novo* Miniprotein-Based Therapies Tackling Challenging Targets**
Ambrus Gordos, Researcher, Protein Design, VRG Therapeutics

ADVANCES IN PEPTIDE ENGINEERING

Long Acting, Stable Urocortin-2 Analogues for the Treatment of Obesity and Diabetes
Dennis Åsberg, PhD, Senior Project Manager, Global Research Technologies, Novo Nordisk A/S

Therapeutic Peptide Generative Models, Scoring Functions and Retrosynthesis
Leonardo De Maria, PhD, Principal Scientist, AstraZeneca R&D

A New Technology for Endotoxin Removal from Biologicals and from Patient Blood
Dirk Linke, PhD, Professor, Molecular Microbiology, Department of Biosciences, University of Oslo

SHORT COURSES* AND TRAINING SEMINARS

All short courses will take place in-person only from 14:00 – 17:00 on 16 November. Our short courses are designed to be instructional, interactive, and provide in-depth information on a specific topic. They allow for one-on-one interaction between the participants and instructors to facilitate the explanation of the more technical aspects that would otherwise not be covered during our main presentations.

SC1: Reinventing Conjugate Therapeutics: Payload Revolution, Target Expansion and Clinical Translation

Lenka Sadilkova, PhD, Director, R&D Program, Eli Lilly ČR, s.r.o.

SC2: Developability of Bispecific Antibodies

Nimish Gera, PhD, Founder and Principal Consultant, MABS R US Consulting

** Separate registration required for Short Courses*

Training SEMINARS

By Cambridge Healthtech Institute

Cambridge Healthtech Institute Training Seminars offer real-life case studies, problems encountered, and solutions applied, along with extensive coverage of the academic theory and background. Each training seminar offers a mix of formal lecture and interactive discussions and activities to maximize the learning experience. These training seminars are led by experienced instructors who will focus on content applicable to your current research and provide important guidance for those new to their fields.



MONDAY, 16 NOVEMBER

TS1A: Introduction to Multispecific Antibodies: History, Engineering, and Applications
G. Jonah Rainey, PhD, Associate Vice President, Eli Lilly and Company

TS2A: Everything You Ever Wanted to Know about Immunogenicity
Chloé Ackaert, PhD, Senior Scientist, Immunogenicity, IQVIA Laboratories
Timothy Hickling, PhD, Consultant, Quasor Ltd.
Sofie Pattyn, Founder & CTO, IQVIA Laboratories

TS3A: Introduction to Machine Learning for Biologics Design
Christopher R. Corbeil, PhD, Research Officer, Human Health Therapeutics, National Research Council Canada

TS4A: Protein Production 201: Applying End-to-End CEPA Workflow
Richard Altman, MS, Field Application Scientist, Thomson Instrument Company

Christopher Cooper, DPhil, Senior Lecturer in Biotechnology, University of Surrey

TUESDAY, 17 NOVEMBER

TS7B: AI-Driven Design of Biologics: A Hands-on Guide to Using State-of-the-Art ML Protein Models
David P. Nannemann, PhD, Vice President, Rosetta Commons Foundation

Hotel & Travel Information

Please visit the pegsummiteurope.com/travel for reserving hotel accommodations and for additional Information.

Conference Venue:
Lisbon Congress Center
Pracas Das Industrias
Lisbon, 1300-307, Portugal

Host Hotels:

Pestana Palace Lisboa
Rua Jau, 54
1300-314, Lisbon, Portugal
Tel: +351 213 615 600

Vila Gale Opera Hotel Lisbon
Travessa Conde da Ponte
1300-141 Lisbon, Portugal
Tel: +351 213 605 400

Hyatt Regency Lisbon
Rua da Junqueira, 63
1300-343 Lisbon, Portugal



SPONSORSHIP OPPORTUNITIES

Comprehensive sponsorship packages allow you to achieve your objectives before, during, and long after the event. Signing on earlier will allow you to maximize exposure to hard-to-reach decision-makers.

PODIUM PRESENTATIONS - AVAILABLE WITHIN MAIN AGENDA!

Showcase your solutions to a guaranteed, targeted audience through a 15- or 30-minute presentation during a specific conference program. Package includes exhibit space, on-site branding, and access to cooperative marketing efforts by CHI. Presentations do sell out early.

ONE-ON-ONE MEETINGS

Work with us to identify your target prospects and we will schedule meetings for you. Think of us as your inside sales team with all your hottest leads in close reach. Opportunities sold on a very limited basis.

INVITATION-ONLY DINNER / HOSPITALITY SUITE

Sponsors will select their top prospects from the conference preregistration list for an evening of networking at the hotel or at a choice local venue. CHI will extend invitations, conduct follow-up and confirm attendees. The evening will be customized to meet with your specific objectives.

EXHIBIT BOOTH SPACE (sold as part of sponsorship packages only)

Exhibitors will enjoy facilitated networking opportunities with over 1,500+ qualified delegates, making it the perfect opportunity to launch a new product, collect feedback, and generate new leads from around the world.

ADDITIONAL SPONSORSHIP & BRANDING OPPORTUNITIES INCLUDE:

- Opening Reception Sponsorship
- Poster Awards Sponsorship
- Literature Distribution
- Conference Tote Bags
- Conference Notebooks

HOW SPONSORING PROMOTES & BENEFITS YOUR BUSINESS:

- Generate qualified leads consisting of actual decision-makers from within your focus area
- Network with over 1,500+ senior-level professionals and generate leads during dedicated exhibit hall hours, lunches, etc.
- Promote your company's participation in the conference materials
- Increase your brand awareness and drive organic traffic to your website through our various marketing campaigns
- Increase Dedicated Networking Time in the Exhibit Hall

FOR ADDITIONAL INFORMATION REGARDING SPONSORSHIP AVAILABILITY, PLEASE CONTACT:

COMPANIES A-K
Jason Gerardi
Sr. Manager, Business Development
781-972-5452 | jgerardi@healthtech.com

COMPANIES L-Z
Ashley Parsons
Manager, Business Development
781-972-1340 | ashleyparsons@healthtech.com

CURRENT SPONSORS

PREMIER SPONSORS

BIOINTRON

danaher

GenScript
Scripting Possibilities

integral molecular

CORPORATE SPONSORS

ABLEXIS
AlivaMab BIOLOGICS

ABSELION

Acro BIOSYSTEMS

ATUM

BIO-RAD

BRUKER

Chemical Computing Group

Cube Biotech

DIMA BIOTECH
Recombinant mAbs and proteins

ENPICOM

evitria
your proteins, reliably delivered

EVONIK
Leading Beyond Chemistry

FairJourney Biologics

FyoniBio
Tailor-made Biopharma Development

GeneFrontier

i3
Your Companion
Life Science Separation

ICOSAGEN

invenra

IQVIA

KACTUS

Malvern Panalytical

mosaic

NONA BIOSCIENCES

nuclera

PROIMMUNE
www.proimmune.com

SARTORIUS

Scala Biodesign

The Jackson Laboratory

TelesisBio

UNCHAINED LABS

WuXi Biologics
Global Solution Provider

CORPORATE SUPPORT SPONSORS

ASIMOV

ATEM
STRUCTURAL DISCOVERY

avsbio

BIOCYTOGEN

bioneer

carterra

CLADE

Creative Biolabs

Deeptope

Demeetra

DPBIO

FUJIFILM
Value from Innovation

Galatek

gator

Gene Universal

GENOVAC

GENOVIS

Kimialys

Kühner shaker

lightcast

LiveDrop

primrose bio

Protein Metrics

ProteoGenix

Quality Assistance

QUANTUM SI

rapid novor

RIC biologics

TSINGKE

XDC
The Bioconjugation Leader

Visit PEGSummitEurope.com to Learn More and to Register